Antibodies
20 October 2016
Omeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy20 October 2016
Ablynx outlines next steps for its anti-IL-6R nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis20 October 2016
FDA Approves Lilly’s LARTRUVO™ (olaratumab) in Combination with Doxorubicin for Soft Tissue Sarcoma19 October 2016
FDA Approves Genentech’s Cancer Immunotherapy TECENTRIQ® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer18 October 2016
CStone Pharmaceuticals’ PD-L1 monoclonal antibody IND has been formally accepted by the CFDA13 October 2016
C2N Diagnostics Completes Phase 1 Clinical Study of C2N-8E12 (ABBV-8E12) Among Individuals with Progressive Supranuclear Palsy13 October 2016
BIOCAD Biotechnology Company Announces the Start of Phase 2 Clinical Trials of an Innovative Drug to Treat Severe Psoriasis11 October 2016
OncoMed Presents Interim Phase 1b Data for Ipafricept and Vantictumab in Pancreatic Cancer at the ESMO 2016 Congress9 October 2016
Dynavax Presents Early Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, at ESMO Annual CongressNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports